	US 11,952,377 B2
	Quinolines and azaquinolines as inhibitors of CD38
Jennifer Downing, Cambridge, MA (US); Kevin Wayne Kuntz, Cambridge, MA (US); Laurie B. Schenkel, Cambridge, MA (US); and Melissa Marie Vasbinder, Cambridge, MA (US)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim (DE)
Filed by BOEHRINGER INGELHEIM INTERNATIONAL GMBH, Ingelheim (DE)
Filed on Jan. 28, 2022, as Appl. No. 17/586,939.
Claims priority of provisional application 63/143,245, filed on Jan. 29, 2021.
Prior Publication US 2022/0242862 A1, Aug. 4, 2022
Int. Cl. C07D 471/04 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01)

CPC C07D 471/04 (2013.01) [C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01)]

9 Claims

1. A compound, which is 2-(1H-imidazol-1-yl)-8(((1r,4r)-4-(2-methoxyethoxy)cyclohexyl)amino)-5-methylpyrido[3,2-d]pyrimidin-6(5H)-one, or a pharmaceutically acceptable salt thereof.